文献速递眼底病与葡萄膜炎

阈下纳秒激光干预年龄相关性黄斑变性:LEAD随机对照临床试验

Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial.
PubMed 文献 · Ophthalmology · 2018-09-20

PURPOSE: There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications.…

要点

  • 总体SNL未显著延缓iAMD进展至晚期AMD(aHR 0.61,95%CI 0.33-1.14,P=0.122)。
  • 事后分析示无RPD者进展延缓(aHR 0.23,95%CI 0.09-0.59,P=0.002)。
  • 伴RPD者进展率数值升高(aHR 2.56,95%CI 0.80-8.18,P=0.112),需谨慎。

核心结论

  • 在无多模态影像(MMI)晚期AMD征象的iAMD患者中,SNL与假治疗总体进展率无显著差异。
  • SNL可能延缓无RPD者的进展,而对伴RPD者可能不适用,临床表型含RPD时应谨慎。
  • 结果支持进一步开展2RT®激光试验,但不应外推至其他短脉冲激光。

研究设计与样本

  • 受试者随机接受2RT® SNL或假治疗,每6个月一次,作用于研究眼。

主要发现

  • 总体进展至晚期AMD未见显著延缓:校正风险比(aHR)0.61,95%CI 0.33-1.14,P=0.122。
  • 事后分析示RPD存在交互效应(校正交互P=0.002):222例(76.0%)基线无RPD者aHR 0.23(95%CI 0.09-0.59,P=0.002)。
  • 70例(24.0%)伴RPD者进展率数值升高:aHR 2.56,95%CI 0.80-8.18,P=0.112。
  • 组间严重不良事件差异无统计学意义。

关键数值与推荐

  • 主要疗效终点为多模态影像(MMI)定义的进展至晚期AMD时间。
  • 安全性以不良事件评估,严重不良事件组间差异无统计学意义。

临床怎么用

  • 对iAMD患者选择SNL治疗前应评估是否伴RPD,伴RPD者不宜使用。
  • 无RPD的iAMD患者或可考虑2RT® SNL以延缓进展,但仍需进一步试验验证。
  • 不可将本研究结论推广至其他短脉冲激光设备。

局限性

  • RPD相关获益与不利均为事后分析,非预设主要终点,证据强度有限。
  • 伴RPD亚组样本量较小(70例),其进展率升高的置信区间跨1且P值未达显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is an urgent need for a more effective intervention to slow or prevent progression of age-related macular degeneration (AMD) from its early stages to vision-threatening late complications. Subthreshold nanosecond laser (SNL) treatment has shown promise in preclinical studies and a pilot study in intermediate AMD (iAMD) as a potential treatment. We aimed to evaluate the safety of SNL treatment in iAMD and its efficacy for slowing progression to late AMD. DESIGN: The Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study is a 36-month, multicenter, randomized, sham-controlled trial. PARTICIPANTS: Two hundred ninety-two participants with bilateral large drusen and without OCT signs of atrophy. METHODS: Participants were assigned randomly to receive Retinal Rejuvenation Therapy (2RT®; Ellex Pty Ltd, Adelaide, Australia) SNL or sham treatment to the study eye at 6-monthly intervals. MAIN OUTCOME MEASURES: The primary efficacy outcome was the time to development of late AMD defined by multimodal imaging (MMI). Safety was assessed by adverse events. RESULTS: Overall, progression to late AMD was not slowed significantly with SNL treatment compared with sham treatment (adjusted hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.33-1.14; P = 0.122). However, a post hoc analysis showed evidence of effect modification based on the coexistence of reticular pseudodrusen (RPD; adjusted interaction P = 0.002), where progression was slowed for the 222 participants (76.0%) without coexistent RPD at baseline (adjusted HR, 0.23; 95% CI, 0.09-0.59; P = 0.002), whereas an increased progression rate (adjusted HR, 2.56; 95% CI, 0.80-8.18; P = 0.112) was observed for the 70 participants (24.0%) with RPD with SNL treatment. Differences between the groups in serious adverse events were not significant. CONCLUSIONS: In participants with iAMD without MMI-detected signs of late AMD, no significant difference in the overall progression rate to late AMD between those receiving SNL and sham treatment were observed. However, SNL treatment may have a role in slowing progression for those without coexistent RPD and may be inappropriate in those with RPD, warranting caution when considering treatment in clinical phenotypes with RPD. Our findings provide compelling evidence for further trials of the 2RT® laser, but they should not be extrapolated to other short-pulse lasers.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018. PMID: 30244144. doi:10.1016/j.ophtha.2018.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。